Clinical Trials · NCT05605964
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sumitomo Pharma America, Inc.
- Enrollment
- 387
- Start date
- Jan 2023
- Locations
- 108 sites, United States
- Primary endpoint
- Number of Patients With Adverse Events and Serious Adverse Events